Modulation of SIV and HIV DNA vaccine immunity by Fas-FasL signaling.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4379579)

Published in Viruses on March 23, 2015


Jiabin Yan1, Juan Carlos Zapata2, Charles David Pauza3, Maria S Salvato4

Author Affiliations

1: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
2: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
3: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
4: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Articles cited by this

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04

Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94

TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 6.40

Vaccine adjuvants: putting innate immunity to work. Immunity (2010) 5.02

The many roles of FAS receptor signaling in the immune system. Immunity (2009) 4.67

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2010) 4.56

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18

Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 4.14

DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10

Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J Virol (1991) 3.15

The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods (1998) 2.78

Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity (2008) 2.62

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 2.54

Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity (2008) 2.48

Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. Immunity (2008) 2.26

Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25

DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23

Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med (2002) 2.20

Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep (2012) 2.06

DNA vaccines: an historical perspective and view to the future. Immunol Rev (2011) 2.02

Cancer therapy using a self-replicating RNA vaccine. Nat Med (1999) 1.76

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75

NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol (2004) 1.71

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71

Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med (2011) 1.66

Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65

FADD: a regulator of life and death. Trends Immunol (2010) 1.51

Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med (2014) 1.40

Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis (2010) 1.40

Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol (2001) 1.39

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38

Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome priming. EMBO Rep (2014) 1.33

Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.32

Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol (1998) 1.30

Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol (2000) 1.29

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A (2010) 1.28

Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25

IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12

Peptide antigen or superantigen-induced down-regulation of TCRs involves both stimulated and unstimulated receptors. J Immunol (1997) 1.11

Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat Med (2011) 1.10

Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis. J Immunol (2007) 1.02

Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology (2009) 1.02

Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine (2004) 1.02

GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One (2010) 1.01

CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses. Blood (2008) 1.00

Enzymatically active single chain caspase-8 maintains T-cell survival during clonal expansion. Cell Death Differ (2010) 0.98

Trypanosoma cruzi infection selectively renders parasite-specific IgG+ B lymphocytes susceptible to Fas/Fas ligand-mediated fratricide. J Immunol (2002) 0.97

The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. Cell Death Dis (2012) 0.89

Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis (2010) 0.88

An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J (2013) 0.86

RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther (2008) 0.86

DNA vaccines and apoptosis: to kill or not to kill? J Clin Invest (2003) 0.85

The degree of apoptosis as an immunostimulant for a DNA vaccine against HIV-1 infection. Vaccine (2006) 0.81